INNOVATION TRENDS IN RHEUMATOID ARTHRITIS THERAPY DEVELOPMENT: MOLECULAR APPROACHES, IMMUNOTHERAPY, AND DRUG DELIVERY SYSTEMS
DOI:
https://doi.org/10.61796/ijmi.v2i2.300Keywords:
Rheumatoid arthritis, Personalized therapy, Drug delivery system, Immunogenicity, BiomarkerAbstract
Objective: This study explores the latest advancements in rheumatoid arthritis (RA) therapy, focusing on molecular approaches, immunotherapy, and drug delivery systems to enhance therapeutic efficacy and personalization. Method: A systematic review of scientific literature and bioinformatics analysis was conducted to identify molecular subgroups of RA and assess the effectiveness of innovative drug delivery systems, including pH-sensitive hydrogels and transfersomal formulations. Comparative studies between rituximab and tocilizumab were also analyzed, particularly in anti-TNF refractory patients. Results: The findings reveal three molecular subgroups of RA based on transcriptomic profiles, enabling more personalized therapeutic strategies. Advanced drug delivery systems demonstrated a 45% improvement in bioavailability compared to conventional oral formulations. Tocilizumab showed higher efficacy than rituximab in patients with low B-cell expression. However, immunogenicity challenges, with anti-drug antibodies reducing therapeutic efficacy by 40-60%, remain significant. Additionally, non-pharmacological therapies, such as acupuncture, reduced systemic complications, including dementia, by 22%. Novelty: This study highlights the importance of personalized RA treatment based on molecular profiling and introduces innovative drug delivery systems, marking a pivotal shift toward more effective and individualized therapeutic strategies. Future research should focus on more precise biomarker identification and tailored therapeutic approaches for distinct molecular subgroups.
References
H.-H. Liao et al., ‘Acupuncture treatment is associated with a decreased risk of dementia in patients with rheumatoid arthritis in Taiwan: A propensity-score matched cohort study’, Integr Med Res, vol. 13, no. 4, p. 101086, Dec. 2024, doi: 10.1016/j.imr.2024.101086.
M. Friedrich, J. Diegelmann, and S. Brand, ‘IL-17A amplifies TNF-alpha-induced inflammation in intestinal epithelial cells via up-regulation of pro-inflammatory chemokines and cytokines including IL-17C and inflammatory bowel disease risk gene transcripts’, Z Gastroenterol, vol. 50, no. 08, Aug. 2012, doi: 10.1055/s-0032-1324107.
J. Biton et al., ‘In Vivo Expansion of Activated Foxp3+ Regulatory T Cells and Establishment of a Type 2 Immune Response upon IL-33 Treatment Protect against Experimental Arthritis’, The Journal of Immunology, vol. 197, no. 5, pp. 1708–1719, Sep. 2016, doi: 10.4049/jimmunol.1502124.
D. Elia, ‘Chronic Inflammatory Arthritis: Ankylosing Spondylitis’, Spinal Diseases and Research, vol. 1, no. 1, pp. 1–3, Jun. 2018, doi: 10.31579/jsdr.2018/004.
V. Strand et al., ‘Immunogenicity of Biologics in Chronic Inflammatory Diseases: A Systematic Review’, BioDrugs, vol. 31, no. 4, pp. 299–316, Jun. 2017, doi: 10.1007/s40259-017-0231-8.
Y. Xu et al., ‘From molecular subgroups to molecular targeted therapy in rheumatoid arthritis: A bioinformatics approach’, Heliyon, vol. 10, no. 16, p. e35774, Aug. 2024, doi: 10.1016/j.heliyon.2024.e35774.
A. Talitckii, J. L. Mangal, B. K. Colbert, A. P. Acharya, and M. M. Peet, ‘Employing Feature Selection Algorithms to Determine the Immune State of a Mouse Model of Rheumatoid Arthritis’, IEEE J Biomed Health Inform, vol. 28, no. 4, pp. 1906–1916, Apr. 2024, doi: 10.1109/jbhi.2023.3327230.
A. Bachhav, P. L. Pingale, and C. D. Upasani, ‘Pharmaceutical development of etodolac transfersomal gel for topical drug delivery system in rheumatoid arthritis’, Journal of Applied Pharmaceutical Research, vol. 12, no. 4, pp. 155–170, Aug. 2024, doi: 10.69857/joapr.v12i4.597.
F. Humby et al., ‘Rituximab versus tocilizumab in anti-TNF inadequate responder patients with rheumatoid arthritis (R4RA): 16-week outcomes of a stratified, biopsy-driven, multicentre, open-label, phase 4 randomised controlled trial’, The Lancet, vol. 397, no. 10271, pp. 305–317, Jan. 2021, doi: 10.1016/s0140-6736(20)32341-2.
E. Karagianni and D. Karakoulas, ‘Unraveling Tourette’s Syndrome: Genetic and Environmental Interactions, Diagnosis Challenges, and Emerging Treatments’, RA JOURNAL OF APPLIED RESEARCH, vol. 10, no. 07, Jul. 2024, doi: 10.47191/rajar/v10i07.02.
J. Park et al., ‘Causal Relationships Between Modifiable Risk Factors of Cognitive Impairment, Cognitive Function, Self-Management, and Quality of Life in Patients With Rheumatic Diseases’, Orthopaedic Nursing, vol. 37, no. 5, pp. 305–315, Sep. 2018, doi: 10.1097/nor.0000000000000481.
M. McMaster, K. Mohr, A. Page, A. Closmore, F. Towne, and B. D. Brooks, ‘Epitope characterization of anti-drug antibodies—a tool for discovery and health: an overview of the necessity of early epitope characterization to avoid anti-drug antibodies and promote patient health’, Expert Opin Biol Ther, vol. 21, no. 6, pp. 705–715, Jan. 2021, doi: 10.1080/14712598.2021.1863942.
D. V Parums, ‘Editorial: Review Articles, Systematic Reviews, Meta-Analysis, and the Updated Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020 Guidelines’, Medical Science Monitor, vol. 27, Aug. 2021, doi: 10.12659/msm.934475.
Y. Sugawara, F. Ahmed, and J. Solomon, ‘Health-related Quality of Life in Patients With Rheumatoid Arthritis (RA) Vs RA-associated Interstitial Lung Disease’, in A39. MANAGEMENT OF INTERSTITIAL LUNG DISEASE AND ITS CO-MORBIDITIES, American Thoracic Society, May 2023, pp. A1514–A1514. doi: 10.1164/ajrccm-conference.2023.207.1_meetingabstracts.a1514.
D. Singh, ‘Challenges in Immunomodulation for Psoriasis: Recent Advancements and Need of Therapies’, Curr Drug ther, vol. 19, no. 3, pp. 275–278, May 2024, doi: 10.2174/0115748855274998231113110529.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Riska Shalu Herawati, Nisrina Kamilia, Shinta Shilkiaturrahma
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
